Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials Drug Efficacy C-POST Trial Efficacy and Safety Eli Lilly Lecanemab DESTINY-Breast09 Trial BREAKWATER Trial Weight Loss Medications

3 ARTICLES

yesterday

FDA Approves Lumvoa for Thyroid Eye Disease

Supported by two positive Phase 3 trials, the approval lets Viridian begin commercial sales, activate a patient-access program, and pursue coverage for people with active or chronic disease.

6 ARTICLES

last wk.

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

35 ARTICLES

last mo.

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

3 ARTICLES

last mo.

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

7 ARTICLES

last mo.

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

3 ARTICLES

last mo.

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

13 ARTICLES

2mo ago

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

6 ARTICLES

2mo ago

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

6 ARTICLES

2mo ago

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

4 ARTICLES

2mo ago

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

3 ARTICLES

2mo ago

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

5 ARTICLES

2mo ago

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

3 ARTICLES

2mo ago

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

19 ARTICLES

2mo ago

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

9 ARTICLES

2mo ago

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

Phase 3 Trials

FDA Approves Lumvoa for Thyroid Eye Disease

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Expands Capvaxive Use to At‑Risk Children and Teens

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Never miss stories about

Phase 3 Trials

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

Never miss stories about

Phase 3 Trials